Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer

Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Related Keywords

United States , ,Accutar Biotechnology Inc ,Drug Administration ,Lijie Fan ,Chief Executive Officer ,Accutar Biotechnology ,Media Contact ,Fda Clearance ,Rend Application ,Prostate Cancer ,Biotechnology Company ,Artificial Intelligence ,Hi ,Drug Discovery ,Us Food And Drug Administration ,Metastatic Castration Resistant Prostate ,Androgen Receptor ,Xbiotech ,